British pharmaceutical company AstraZeneca, illustration.

-

Gonzalo Fuentes / AP / SIPA

It won't be for now.

An authorization from January within the European Union of the anti-Covid vaccine developed by the AstraZeneca group with the University of Oxford, which has just been approved in the United Kingdom, seems unlikely, estimated the European Agency drugs (EMA).

"No formal marketing authorization has yet been submitted to the EMA" for this vaccine, meaning that a timetable could not be established for the moment, told AFP the agency based in Amsterdam.

AstraZeneca / Oxford vaccine currently under "continuous review"

EMA deputy executive director Noël Wathion told Belgian daily Het Nieuwsblad on Tuesday that a possible authorization during the next month is "unlikely", comments confirmed by the agency on Tuesday evening.

The AstraZeneca / Oxford vaccine is currently undergoing a 'continuous review', which allows the EMA to review vaccine safety and efficacy data as they become available, even before a formal request. authorization is filed by the manufacturer.

This procedure makes it possible to speed up the assessment of a marketing authorization application once it has been formulated.

The EMA authorized the Pfizer / BioNTech Covid-19 vaccine on December 21, for which the European Commission immediately gave the green light, and must decide on January 6 on that of Moderna.

Health

AstraZeneca says it has 'winning formula' for vaccine ahead of UK decision

Health

AstraZeneca laboratory and Russia want to combine their vaccines

  • Covid 19

  • Vaccination

  • Vaccine

  • Health

  • Coronavirus

  • Society